Clinical Trial Update: A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 study evaluating apalutamide in combination with a GnRH agonist for androgen receptor-positive salivary gland carcinoma; results were posted in July 202…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Salivary Gland Neoplasms

Drugs mentioned

• Apalutamide (apalutamide)
• GnRH agonist (gonadotropin-releasing hormone agonist)

Snippet

Sponsor: Janssen Pharmaceutical K.K. | Conditions: Salivary Gland Neoplasms | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2022-07-06